|Awarded On||February 19, 2020|
|Title||Development of a First-in-Class Small Molecule, TASIN, for Targeting Truncated APC Mutations for the Treatment of Colorectal Cancer (CRC)|
|Program||Product Development Research|
|Award Mechanism||Seed Awards for Product Development Research|
|Institution/Organization||Barricade Therapeutics, Corp.|
|Principal Investigator/Program Director||Neil C Thapar|
*Pending contract negotiation
Over 1.8 million people are estimated to be stricken with colorectal cancer (CRC) every year (3rd most common cancer), and over 880,000 will die (2nd most common cancer). While improvements in prevention and screening have led to increased survival over the past several decades, metastatic cancer still has a poor prognosis (11% 5-year survival) despite best available therapies. Treatment for CRC relies heavily on non-specific chemotherapy drugs with harsh side effects. Under prior CPRIT research awards, scientists at the University of Texas Southwestern (UTSW) identified a class of highly specific drugs for CRC, referred to as TASINs, that selectively inhibit a mutated gene (adenomatous poly...